Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Cephalon
Actavis Generics Allergan's generics business |
| gptkbp:CEO |
Kåre Schultz
|
| gptkbp:clinicalTrials |
Conducts clinical trials
Focus on innovative therapies Focus on generics |
| gptkbp:communityPrograms |
Health education
Volunteerism Patient support programs Disease awareness campaigns Access to healthcare initiatives |
| gptkbp:employees |
Approximately 40,000
|
| gptkbp:founded |
1901
|
| gptkbp:globalPresence |
Operations in over 60 countries
|
| gptkbp:headquarters |
Amsterdam,_Netherlands
|
| https://www.w3.org/2000/01/rdf-schema#label |
Teva Pharmaceuticals Europe
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:market |
Specialty pharmaceuticals
Generic_pharmaceuticals |
| gptkbp:operatesIn |
Europe
|
| gptkbp:parentCompany |
gptkb:Teva_Pharmaceutical_Industries
|
| gptkbp:partnerships |
Academic institutions
Various healthcare organizations Biotech_companies |
| gptkbp:productLine |
Asthma
Gastroenterology Multiple sclerosis Oncology Pain management Transplantation Urology Neurology Parkinson's disease Antibiotics Vaccines Dermatology Chronic obstructive pulmonary disease (COPD) Biologics Cardiovascular Nutraceuticals Over-the-counter medications Hormonal therapies Biosimilars |
| gptkbp:products |
Specialty medicines
Generic_drugs |
| gptkbp:regulatoryCompliance |
FDA_approved_products
EMA_approved_products |
| gptkbp:researchAndDevelopment |
Focus on oncology
Focus on respiratory diseases Focus on CNS disorders |
| gptkbp:revenue |
$16.7 billion (2020)
|
| gptkbp:subsidiary |
gptkb:Teva_Pharmaceutical_Industries
|
| gptkbp:sustainabilityInitiatives |
Community engagement
Environmental responsibility Access to medicines |
| gptkbp:website |
www.tevapharm.com
|